Literature DB >> 29294263

[NAFLD pathogenesis in the light of recent research].

Marcin Banaszczak1, Ewa Stachowska1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. Nowadays, the number of people with type II diabetes and hypertension is growing. These symptoms belong to metabolic syndrome and the liver manifestation of this disease is NAFLD. Most people suffering from NAFLD are obese but this disease can also affect the lean individuals. This disease in extreme cases can lead to liver fibrosis and cirrhosis. Although NAFLD remains largely asymptomatic for the most of the time it can progress to a severe form of disease called nonalcoholic steatohepatitis (NASH) or even hepatocellular carcinoma. In this review we describe a role of factors that influence NAFLD pathogenesis such as: insulin resistance, epigenetic factors, adipokine dysfunction, intestinal flora disorder, oxidative stress and markers of inflammatory states in the form of fatty acid derivatives.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; pathogenesis

Mesh:

Year:  2017        PMID: 29294263

Source DB:  PubMed          Journal:  Postepy Biochem        ISSN: 0032-5422


  3 in total

1.  Eicosapentaenoic acid loaded silica nanoemulsion attenuates hepatic inflammation through the enhancement of cell membrane components.

Authors:  Jihan Hussein; Mona A El-Bana; Zakaria El-kHayat; Mehrez E El-Naggar; Abdel Razik Farrag; Dalia Medhat
Journal:  Biol Proced Online       Date:  2022-09-07       Impact factor: 7.717

2.  Impact of One-Year Dietary Education on Change in Selected Anthropometric and Biochemical Parameters in Children with Excess Body Weight.

Authors:  Kamilla Strączek; Anita Horodnicka-Józwa; Justyna Szmit-Domagalska; Tomasz Jackowski; Krzysztof Safranow; Elżbieta Petriczko; Mieczysław Walczak
Journal:  Int J Environ Res Public Health       Date:  2022-09-16       Impact factor: 4.614

3.  Arachidonic Acid as an Early Indicator of Inflammation during Non-Alcoholic Fatty Liver Disease Development.

Authors:  Klaudia Sztolsztener; Adrian Chabowski; Ewa Harasim-Symbor; Patrycja Bielawiec; Karolina Konstantynowicz-Nowicka
Journal:  Biomolecules       Date:  2020-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.